Clinical Trial Update: A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effect of Enantone LP 11.25 mg (leuprorelin) on histological progression in indolent prostate cancer; study completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enantone LP 11.25 mg (leuprorelin)

Snippet

Sponsor: Takeda | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-04-16